uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab
Karolinska Inst, Sci Life Lab, Drug Discovery & Dev Platform, Stockholm, Sweden.;Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.;Univ KwaZulu Natal, Catalysis & Peptide Res Unit, Durban, South Africa..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för läkemedelskemi, Avdelningen för organisk farmaceutisk kemi. Uppsala universitet, Science for Life Laboratory, SciLifeLab. Karolinska Inst, Physiol & Pharmacol, Stockholm, Sweden..
KellSa Sas, Str Campo & Zampe 12, I-13900 Biella, BI, Italy..
2017 (engelsk)Inngår i: FUTURE SCIENCE OA, ISSN 2056-5623, Vol. 3, nr 2, artikkel-id FSO176Artikkel i tidsskrift (Annet (populærvitenskap, debatt, mm)) Published
Abstract [en]

The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish academic researchers with large-scale technologies for molecular biosciences with a focus on health and environment. SciLifeLab was created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University, and has recently expanded to other Swedish university locations. The primary goal of the SciLifeLab DDD is to support selected academic discovery and development research projects with tools and resources to discover novel lead therapeutics, either molecules or human antibodies. Intellectual property developed with the help of SciLifeLab DDD is wholly owned by the academic research group. The bulk of SciLifeLab DDD's research and service activities are funded from the Swedish state, with only consumables paid by the academic research group through individual grants.

sted, utgiver, år, opplag, sider
2017. Vol. 3, nr 2, artikkel-id FSO176
Emneord [en]
academic drug discovery, academic medical research, antibody therapeutics, biopharma, drug development, drug discovery, pharma research, small molecules
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-331950DOI: 10.4155/fsoa-2017-0013ISI: 000405987900016PubMedID: 28670468OAI: oai:DiVA.org:uu-331950DiVA, id: diva2:1151386
Tilgjengelig fra: 2017-10-23 Laget: 2017-10-23 Sist oppdatert: 2018-01-13bibliografisk kontrollert

Open Access i DiVA

fulltext(1279 kB)70 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1279 kBChecksum SHA-512
33d1b96c7aca5fb70efcffdac8217403eff36b4e020eea8dc0fa334476f7b0078af9732449bb11bb2356173d772f422d7c4aeff0d1a55ae21701e66519d7253e
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Sandberg, Kristian

Søk i DiVA

Av forfatter/redaktør
Sandberg, Kristian
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 70 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 330 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf